Abstract Background Escin is a triterpenoid saponin extracted from the dried mature seeds of Aesculus wilsonii Rehd. (Hippocastanaceae). This study aimed to investigate the effects of Escin on dextrose sodium sulfate (DSS)-induced mice. Methods Our investigation included in vivo assessments of Escin’s therapeutic potential against DSS-induced colitis through efficacy and safety evaluation. Potential targets of Escin were identified using a network pharmacology approach combined with molecular docking. Additionally, flow cytometric analysis was performed to evaluate immune cell subsets and macrophage polarization within spleen and colon tissues. In vitro experiments utilized lipopolysaccharide (LPS)-stimulated RAW264.7 cells and bone marrow-derived macrophages (BMDM) to elucidate relevant mechanisms. Results Escin demonstrated significant therapeutic potential against DSS-induced colitis by ameliorating disease symptoms, restoring intestinal barrier integrity, and reducing proinflammatory cytokine production in colonic tissues. Furthermore, it demonstrated favorable hepatorenal safety profiles. Network pharmacology analysis identified the NF-κB signaling pathway as a central target, and molecular docking further revealed strong binding affinities between Escin and key proteins involved in NF-κB signaling, such as IKBKB and TNF. Flow cytometry revealed that Escin exerted immunomodulatory effects in vivo by suppressing pro-inflammatory M1 macrophages while promoting anti-inflammatory M2 macrophages within colon tissues. In vitro, Escin inhibited blockade of NF-κB activation in both LPS-stimulated BMDM and RAW264.7 cells, and Escin exhibited robust anti-inflammatory activity in LPS-stimulated BMDM by remodeling macrophage polarization. Conclusion Escin ameliorates experimental colitis through remodeling macrophage polarization through NF-κB signaling pathways. Escin emerges as a promising candidate for clinical therapy targeting colitis. References: 1 D. B. Graham, R. J. Xavier, “Pathway Paradigms Revealed From the Genetics of Inflammatory Bowel Disease,” Nature 578 (2020): 527-539. 2 S. C. Ng, H. Y. Shi, N. Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies,” Lancet 390 (2017): 2769-2778. 3 L. Xu, B. He, Y. Sun, et al., “Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study,” Clin Gastroenterol Hepatol 21 (2023): 3379-3386.e29. 4 S. H. Park, S. H. Park, “Personalized Medicine in Inflammatory Bowel Disease: Perspectives on Asia,” J Gastroenterol Hepatol 37 (2022): 1434-1445. 5 M. Agrawal, K. H. Allin, F. Petralia, et al., “Multiomics to Elucidate Inflammatory Bowel Disease Risk Factors and Pathways,” Nat Rev Gastroenterol Hepatol 19 (2022): 399-409. 6 A. Gilliland, J. J. Chan, T. J. De Wolfe, et al., “Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care,” Gastroenterology 166 (2024): 44-58. 7 C. Steenholdt, J. Brynskov, O. Ø. Thomsen, et al., “Individualised Therapy Is More Cost-Effective Than Dose Intensification in Patients With Crohn’s Disease Who Lose Response to Anti-TNF Treatment: A Randomised Controlled Trial,” Gut 63 (2014): 919-927. 8 H. Yang, B. Li, Q. Guo, et al., “Systematic Review With Meta-Analysis: Loss of Response and Requirement of Ustekinumab Dose Escalation in Inflammatory Bowel Diseases,” Aliment Pharmacol Ther 55 (2022): 764-777. 9 G. Rogler, A. Singh, A. Kavanaugh, et al., “Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management,” Gastroenterology 161 (2021): 1118-1132. 10 A. M. Hine, P. N. Loke, “Intestinal Macrophages in Resolving Inflammation,” J Immunol 203 (2019): 593-599. 11 L. Tian, J. L. Zhao, J. Q. Kang, et al., “Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling,” Front Immunol 12 (2021): 740565. 12 X. Zhu, Q. Yao, P. Yang, et al., “Multi-Omics Approaches for In-Depth Understanding of Therapeutic Mechanism for Traditional Chinese Medicine,” Front Pharmacol 13 (2022): 1031051. 13 L. Zhao, Y. Y. Zhao, F. X. Zhao, “Fuzheng Huoxue Decoction Combined With Infliximab in the Treatment of Crohn’s Disease,” China J Chin Med 37 (2022): 1071–1075. 14 S. Ben-Horin, N. Salomon, G. Karampekos, et al., “Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial,” Clin Gastroenterol Hepatol 22 (2024): 347-356.e6. 15 W. Sun, Q. Yin, H. Wan, et al., “Characterization of the Horse Chestnut Genome Reveals the Evolution of Aescin and Aesculin Biosynthesis,” Nat Commun 14 (2023): 6470. 16 Q. Zheng, T. Wang, S. Wang, et al., “The Anti-Inflammatory Effects of Saponins From Natural Herbs,” Pharmacol Ther 269 (2025): 108827. 17 X. Sun, Z. Liu, L. Zhou, et al., “Escin Avoids Hemorrhagic Transformation in Ischemic Stroke by Protecting BBB Through the AMPK/Cav-1/MMP-9 Pathway,” Phytomedicine 120 (2023): 155071. 18 F. Yang, “Impact of Sodium Aescinate Combined With Bone Peptide Injection on Limb Swelling and Fracture Healing in Elderly Patients With Calcaneal Fracture After Operation,” Chin J Clin Rational Drug Use 14 (2021): 39-44. 19 H. M. Shi, “Clinical Efficacy and Safety of Mannitol, Fructose Combined With β-Aescin Sodium in the Treatment of Cerebral Hemorrhage,” J Med Theory Pract 34 (2021): 1136-1137. 20 L. Zhang, M. Fei, H. Wang, et al., “Sodium Aescinate Provides Neuroprotection in Experimental Traumatic Brain Injury via the Nrf2-ARE Pathway,” Brain Res Bull 157 (2020): 26-36. 21 B. L. Zhang, D. Li, F. Wang, et al., “Effect of Preconditioning With Sodium Aescinate on Ischemia-Reperfusion Injury of Skeletal Muscle,” Orthop J China 28 (2020): 1985-1988. 22 W. Xin, L. Zhang, H. Fan, et al., “Escin Attenuates Acute Lung Injury Induced by Endotoxin in Mice,” Eur J Pharm Sci 42 (2011): 73-80. 23 F. M. Salinas, L. Vázquez, M. V. Gentilini, et al., “Aesculus Hippocastanum L. Seed Extract Shows Virucidal and Antiviral Activities Against Respiratory Syncytial Virus and Reduces Lung Inflammation In Vivo,” Antiviral Res 164 (2019): 1-11. 24 F. A. Peñaranda Figueredo, J. Vicente, A. A. Barquero, et al., “Aesculus Hippocastanum Extract and the Main Bioactive Constituent β-Escin as Antiviral Agents Against Coronaviruses, Including SARS-CoV-2,” Sci Rep 14 (2024): 6418. 25 M. Sikorska, M. Dutkiewicz, O. Zegrocka-Stendel, et al., “Beneficial Effects of β-Escin on Muscle Regeneration in Rat Model of Skeletal Muscle Injury,” Phytomedicine 93 (2021): 153791. 26 X. Wang, C. Cui, X. Meng, et al., “Chiral Supramolecular Hydrogel Enhanced Transdermal Delivery of Sodium Aescinate to Modulate M1 Macrophage Polarization Against Lymphedema,” Adv Sci (Weinh) 11 (2024): e2303495. 27 M. Li, F. Fu, T. Wang, “Escin Alleviates Cerebral Ischemia-Induced Intestinal Pyroptosis via the GR-Dependent p38 MAPK/NF-κB Signaling and NLRP3 Inflammasome Activation,” Int Immunopharmacol 138 (2024): 112592. 28 Y. X. Ding, G. W. Eerdunagula, S. J. Duan, et al., “Escin Ameliorates the Impairments of Neurological Function and Blood Brain Barrier by Inhibiting Systemic Inflammation in Intracerebral Hemorrhagic Mice,” Exp Neurol 337 (2021): 113554. 29 D. K. Sahoo, R. M. Heilmann, B. Paital, et al., “Oxidative Stress, Hormones, and Effects of Natural Antioxidants on Intestinal Inflammation in Inflammatory Bowel Disease,” Front Endocrinol (Lausanne) 14 (2023): 1217165. 30 G. P. Ramos, K. A. Papadakis, “Mechanisms of Disease: Inflammatory Bowel Diseases,” Mayo Clin Proc 94 (2019): 155-165. 31 M. Elshal, S. H. Hazem, “Escin Suppresses Immune Cell Infiltration and Selectively Modulates Nrf2/HO-1, TNF-α/JNK, and IL-22/STAT3 Signaling Pathways in Concanavalin A-Induced Autoimmune Hepatitis in Mice,” Inflammopharmacology 30 (2022): 2317-2329. 32 Y. Du, Y. Song, L. Zhang, et al., “Combined Treatment With Low Dose Prednisone and Escin Improves the Anti-Arthritic Effect in Experimental Arthritis,” Int Immunopharmacol 31 (2016): 257-265.
Zhou et al. (Thu,) studied this question.